Nyxoah S.A. (NASDAQ:NYXH - Get Free Report) traded up 1.2% on Friday . The company traded as high as $9.16 and last traded at $9.15. 31,729 shares were traded during mid-day trading, a decline of 53% from the average session volume of 66,965 shares. The stock had previously closed at $9.04.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on NYXH shares. HC Wainwright reaffirmed a "buy" rating and set a $17.00 price target on shares of Nyxoah in a research note on Friday, December 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $16.00 target price on shares of Nyxoah in a research report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $17.00.
View Our Latest Research Report on NYXH
Nyxoah Stock Up 1.2 %
The stock has a fifty day moving average price of $8.44 and a two-hundred day moving average price of $8.47. The company has a market cap of $228.20 million, a price-to-earnings ratio of -4.89 and a beta of 1.35. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Nyxoah stock. Kovack Advisors Inc. bought a new position in shares of Nyxoah S.A. (NASDAQ:NYXH - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,000 shares of the company's stock, valued at approximately $96,000.
Nyxoah Company Profile
(
Get Free Report)
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Read More
Before you consider Nyxoah, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nyxoah wasn't on the list.
While Nyxoah currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
